Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2025Frontiers in ImmunologyOpen Access

Hes1 in malignant tumors: from molecular mechanism to therapeutic potential

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZuo‐Feng ZhangQZQian ZhangCGCheng Guo

Discussion

Loading...

Member takes

Overview

Review finds that targeting Hes1 may improve outcomes in malignant tumors by influencing immune microenvironment and tumor progression.

Key Points

  • Hes1 is a transcriptional regulator involved in the progression of malignant tumors through immune microenvironment modulation.
  • High Hes1 expression correlates with tumor stage, prognosis, and resistance to treatment across multiple malignancies.
  • Targeting Hes1 presents a promising therapeutic strategy in cancer treatment and immunotherapy.
  • Recent studies reveal complex interactions of Hes1 with pathways like Notch, JAK/STAT, and Wnt/β-catenin in tumor progression.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/689a0f93e6551bb0af8d127dhttps://doi.org/10.3389/fimmu.2025.1585624
View Full Paper
Ask AI
Bookmark
Share